If you have been reading about synaptic plasticity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
=== Indian Ocean === As of 2022, India is one of five countries that produced 50% of the world fish bladder supply and 70% of its value. The Indian swim bladder trade dates back to the 1800s for isinglass production, and has been regulated by the Indian government under the Harmonized System since 2002. Increasing demand from East Asia has driven fishing of croakers in particular, fueling an auction market in the major fishing and export ports Chennai, Kolkata, Mumbai and Veraval. There is little domestic Indian demand for fish maw. Bangladesh has a developing fish maw trade in the Karnaphuli delta targeting the high-value maws of Johnius coitor (datina koral) and Pomadasys argenteus, and Indian salmon. Less valuable but still traded fish maw species include Pangasius hypophthalmus, Labeo rohita, Catla catla, Wallago attu, and Leptomelanosoma indicum.
Diabetes mellitus similar but not identical to human Type I (insulin deficiency): The disease occurs in middle-aged Samoyeds, the mean age at diagnosis is seven years. The cause is a chronic inflammation of the pancreas and/or autoimmune destruction of the beta cells of islets of Langerhans. Moreover, autoantibodies to insulin were found in affected dogs. Several genetic markers are being discussed as possible causes. Progressive retinal atrophy (PRA) caused by a frameshift mutation in the RPRG locus of the X chromosome. The disease leads to a slowly progressive loss of vision, which eventually leads to blindness. The first symptoms appear between two and five years of age. The disease corresponds to the X-linked PRA type 3 in humans. Short legs in conjunction with eye abnormalities: a genetic defect at the COL2A1 locus leads to disproportionate dwarfism due to short limbs in connection with cataracts, malformations of the retina or retinal detachment, liquefaction of the vitreous and a persistent hyaloid artery. The malformations of the retina are dominant (i.e. they occur in heterozygous dogs); the other symptoms are recessive, so that they are expressed only in homozygous dogs. These conditions have no effect on the expression of the protein opticin. Pulmonary stenosis occurs more frequently in Samoyeds in comparison with other breeds. The disease can cause shortness of breath, cardiac arrhythmias and rapid fatigue when moving, and increases the risk of congestive heart failure. Hip dysplasia is also a concern for Samoyeds.
== Metal sulfides == Sulfur reacts with many metals. Electropositive metals give polysulfide salts. Copper, zinc and silver are tarnished by sulfur. Although many metal sulfides are known, most are prepared by high temperature reactions of the elements. Sulfide minerals contain the sulfide (S2-) or disulfide (S22-) anions. Typical examples are:
== History == Evidence emerged by the end of the 1970s that the newly discovered proton pump (H+/K+ ATPase) in the secretory membrane of the parietal cell was the final step in acid secretion. Literature from anaesthetic screenings led attention to the potential antiviral compound pyridylthioacetamide which after further examination pointed the focus on an anti-secretory compound with unknown mechanisms of action called timoprazole. Timoprazole is a pyridylmethylsulfinyl benzimidazole and appealed due to its simple chemical structure and its surprisingly high level of anti-secretory activity. Optimization of substituted benzimidazoles and their antisecretory effects were studied on the newly discovered proton pump to obtain higher pKa values of the pyridine, thereby facilitating accumulation within the parietal cell and increasing the rate of acid-mediated conversion to the active mediate. As a result of such optimization the first proton pump inhibiting drug, omeprazole, was released on the market. Other PPIs like lansoprazole and pantoprazole would follow in its footsteps, claiming their share of a flourishing market, after their own course of development.
Sources: en.wikipedia.org
Depyrogenation refers to the removal of pyrogens from solutions, most commonly from injectable pharmaceuticals. A pyrogen is defined as any substance that can cause a fever. Bacterial pyrogens include endotoxins and exotoxins, although many pyrogens are endogenous to the host. Endotoxins include lipopolysaccharide (LPS) molecules found as part of the cell wall of Gram-negative bacteria, and are released upon bacterial cell lysis. Endotoxins may become pyrogenic when released into the bloodstream or other tissue where they are not usually found. Although the colon contains Gram-negative bacteria in abundance, they do not cause a pyrogenic effect as the bacteria are not undergoing gross lysis, and the immune system is not exposed to free endotoxin while the colonic wall is intact. When LPS is released upon bacterial cell lysis, the lipid A component is first bound by serum LPS-Binding Protein (LBP) and then transferred to CD14 (either free CD14 in the serum or bound to the cell surface of macrophages or monocytes). This monomerises the aggregated LPS, as the LPS receptor Toll-like Receptor 4 (TLR4) cannot recognise LPS while aggregated. Monomeric LPS is then transferred to MD-2 pre-complexed with TLR4 on macrophages and monocytes. This leads to release of pro-inflammatory cytokines and nitric oxide, which may lead ultimately to septic shock depending on the strength of response. Vascular endothelial cells also express TLR4 and MD-2 and so respond to LPS directly, as well as via cytokines and nitric oxide.
=== Mark McVeigh Era (2026–present) === On Monday 24th of August 2026, Mark McVeigh was appointed Senior Coach of Essendon, a three year contract running through to the end of the 2029 AFL season. Club President Andrew Welsh said the decision was unanimously supported by the club board, and stating in a press release that "we have been extremely clear on the strategy and direction of this football club. We are building the next successful era for Essendon, with a view to playing finals, winning finals and competing for premierships. Mark is the best coach to take us forward to achieve that."
Hari, Johann (2015). Chasing the Scream: The First and Last Days of the War on Drugs. London; New York: Bloomsbury. ISBN 978-1-62040-890-2. Blanchard, Michael; Chin, Gabriel J. (1998). "Identifying the Enemy in the War on Drugs: A Critique of the Developing Rule Permitting Visual Identification of Indescript White Powders in Narcotics Prosecutions". American University Law Review (47): 557. SSRN 1128945. Daniel Burton-Rose, The Celling of America: An Inside Look at the U.S. Prison Industry. Common Courage Press, 1998. Stephanie R. Bush-Baskette, "The War on Drugs as a War on Black Women", in Meda Chesney-Lind and Lisa Pasko (eds.), Girls, Women, and Crime: Selected Readings. Sage, 2004. Chin, Gabriel (2002). "Race, the War on Drugs and the Collateral Consequences of Criminal Conviction". Gender, Race & Justice (6): 253. SSRN 390109. Alexander Cockburn and Jeffrey St. Clair, Whiteout: The CIA, Drugs and the Press. New York: Verso, 1998. Mitchell Earlywine, Understanding Marijuana: A New Look at the Scientific Evidence. New York: Oxford University Press, 2005. Kathleen J. Frydl, The Drug Wars in America, 1940–1973. New York: Cambridge University Press, 2013. Nunn, Kenneth B. (2002). "Race, Crime and the Pool of Surplus Criminality: Or Why the War on Drugs Was a War on Blacks". Gender, Race & Justice. 6 (6): 381. Tony Payan, "A War that Can't Be Won." Tucson: The University of Arizona Press, 2013. Preston Peet, Under the Influence: The Disinformation Guide to Drugs. The Disinformation Company, 2004. Thomas C.
He proposed a scenario whereby the critical electrochemistry of enzymatic reactions would have necessitated retention of the specific nucleotide moieties of the original RNA-based enzymes carrying out the reactions, while the remaining structural elements of the enzymes were gradually replaced by protein, until all that remained of the original RNAs were these nucleotide cofactors, "fossils of nucleic acid enzymes".
=== Hydromorphone === Hydromorphone is derived from morphine and may be used as an alternative to it. It has a high first-pass metabolism when given orally, and is primarily glucuronidated in the liver to hydromorphone-3-glucoronide (H3G). 75% of hydromorphone is renally excreted, with 7% excreted as the parent opiate.
Sources: en.wikipedia.org
Proteins that are needed in a particular region of the cell can also be translated there; in such a case, the 3' UTR may contain sequences that allow the transcript to be localized to this region for translation. Some of the elements contained in untranslated regions form a characteristic secondary structure when transcribed into RNA. These structural mRNA elements are involved in regulating the mRNA. Some, such as the SECIS element, are targets for proteins to bind. One class of mRNA element, the riboswitches, directly bind small molecules, changing their fold to modify levels of transcription or translation. In these cases, the mRNA regulates itself.
==== Role of dopamine and glutamate ==== Dopamine is the primary neurotransmitter of the brain's reward system, and also has roles in movement, emotion, cognition and motivation. Natural rewards such as eating, and recreational drug use, both trigger dopamine release, which underlies their reinforcing quality. Excessive intake of many types of addictive drugs results in repeated release of high amounts of dopamine, which in turn affects the reward pathway directly through heightened dopamine receptor activation. Prolonged and abnormally high levels of dopamine in the synaptic cleft can induce receptor downregulation in the neural pathway. Downregulation of mesolimbic dopamine receptors can result in a decrease in the sensitivity to natural reinforcers. Drug seeking is driven by glutamatergic projections from the prefrontal cortex to the nucleus accumbens, and chronic drug exposure produces lasting glutamate-mediated changes along this route.
=== Suicide === Antidepressants may increase the risk of suicidal thoughts and behaviors in children and young adults. Close monitoring for the emergence of suicidal thoughts and behaviors is thus recommended.
Such use is prohibited by the rules of the governing bodies of most sports. AAS use occurs among adolescents, especially by those participating in competitive sports. It has been suggested that the prevalence of use among high-school students in the U.S. may be as high as 2.7%.
== History == In 1997, Hong Kong molecular biologist Dennis Lo and his team first employed the Y-PCR assay to identify fetal Y chromosome sequences (because Y-specific sequences are genetic sequences of the fetus not in the maternal genome) in maternal plasma samples. For this groundbreaking work, Lo was honored with the 2022 Lasker DeBakey Clinical Medical Research Award.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.